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Abstract
Background: Women living with HIV (WHIV) are disproportionately impacted by cervical dysplasia and cancer. The
burden is greatest in low-income countries where limited or no access to screening exists. The goal of this study
was to describe knowledge and intentions of WHIV towards HPV self-collection for cervical cancer screening, and to
report on factors related to HPV positivity among women who participated in testing.
Methods: A validated survey was administered to 87 HIV positive women attending the Kisenyi Health Unit aged
30–69 years old, and data was abstracted from chart review. At a later date, self-collection based HPV testing was
offered to all women. Specimens were tested for high risk HPV genotypes, and women were contacted with results
and referred for care. Descriptive statistics, Chi Square and Fischer-exact statistical tests were performed.
Results: The vast majority of WHIV (98.9%) women did not think it necessary to be screened for cervical cancer and
the majority of women had never heard of HPV (96.4%). However, almost all WHIV found self-collection for cervical
cancer screening to be acceptable. Of the 87 WHIV offered self-collection, 40 women agreed to provide a sample at
the HIV clinic. Among women tested, 45% were oncogenic HPV positive, where HPV 16 or 18 positivity was 15%
overall.
Conclusions: In this group of WHIV engaged in HIV care, there was a high prevalence of oncogenic HPV, a large
proportion of which were HPV genotypes 16 or 18, in addition to low knowledge of HPV and cervical cancer
screening. Improved education and cervical cancer screening for WHIV are sorely needed; self-collection based
screening has the potential to be integrated with routine HIV care in this setting.
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Background
Cervical cancer is a largely preventable and curable disease
that affects over half a million women each year, with the
greatest impact in low and middle income countries
(LMIC) where access to screening, diagnosis, and treat-
ment are extremely limited [1]. As a result, most people in
these regions are diagnosed with cervical cancer at a late
stage [2]. With this delayed diagnosis, more resources are
required for treatment, which increases demands on
already overloaded tertiary care centers. Uganda has one
of the highest age-standardized incidence rates of cervical
cancer globally (41.7/100 000 person-years) at almost six
times the rate in high income countries, in addition to a
high prevalence of human immunodeficiency virus (HIV)
[3]. It is well established that oncogenic types of the hu-
man papillomavirus (HPV) are the main causative agents
of cervical cancer [4]. Primary prevention with the HPV
vaccine has not been rolled out in most LMIC including
Uganda, and the risk for cervical cancer will remain for de-
cades [5]. Characterized by suppressed immune function,
women living with HIV (WHIV) are more likely to have
persistent HPV infection and simultaneous infection with
more than one strain of HPV putting them at higher risk
for cervical dysplasia and invasive cervical cancer [6–8].
Cervical cancer is an AIDS-defining illness [9] that
remains a threat in the era of combination antiretroviral
treatment (cART) which have little to no effect on the
natural history of cervical cancer [7, 10].
In most LMIC, visual inspection with acetic acid
(VIA) is the standard of care for cervical cancer screening,
which requires trained health personnel to perform pelvic
exams, and willingness by women to attend a clinic and
undergo an invasive examination. This is a barrier to
effective cervical cancer screening for many women in
LMIC settings [11]. VIA brings additional challenges in
WHIV who are more likely to have false positive examina-
tions that lead to unnecessary and potentially harmful
treatments. An innovative and feasible method of cervical
cancer screening is emerging with the introduction of self-
collection by vaginal swab for oncogenic HPV DNA
testing. By avoiding the need for a pelvic examination
this technology can significantly decrease the demand on
trained healthcare providers with additional benefits of low
cost and minimal infrastructure requirements [8, 12, 13].
With HPV DNA testing there is also the option to offer
self-collection based screening where sample collection
can be performed by women in their own homes, further
reducing barriers. The Advances in Screening and Pre-
vention in Reproductive Cancers (ASPIRE) project,
based in Uganda, was developed to examine innovations
in cancer prevention for women in LMIC [14–17].
Although other studies in sub-Saharan Africa have exam-
ined attitudes of WHIV to cervical cancer screening, none
have specifically addressed self-collection of HPV as a
screening modality in this population [18]. To further
understand the attitudes of WHIV towards self-collected
specimens for cervical cancer screening, we surveyed
WHIV in Kisenyi, Uganda, to explore their intention to
participate in self-collection based cervical cancer
screening, and offered women self-collection based
testing at the local HIV clinic. This information will
guide programming to engage women with HIV in cer-
vical cancer screening.
Methods
Design, setting and study population
The study design was a cross-sectional survey of know-
ledge, attitudes and behaviours towards self-collected
sampling for cervical cancer screening in WHIV, who
were then invited to participate in self-collection based
screening. Interviews with WHIV and screening were con-
ducted at a satellite HIV clinic of the Infectious Disease
Institute (IDI) located at the Kisenyi Health Unit in an
impoverished area of Kampala, Uganda. WHIV aged
30–69 years old attending a routine appointment for
their HIV care were invited to participate by a member
of the Friends Council, an HIV positive peer group
between July and August 2013. An additional inclusion
criterion was access to a mobile telephone. Women
were excluded if they had previously had a hysterectomy,
cervical cancer or they were unable to provide consent.
Ethics approval for the study was obtained from the
Research Ethics Board of the University of British
Columbia (H09-02935-A013) and Makerere University
(H13-02117).
Survey & chart review
A structured questionnaire was created based on a pre-
viously validated survey using the Theory of Planned
Behaviour exploring women’s intentions to provide a
self-collected specimen for cervical cancer screening
[14]. Items were reviewed with local and international
experts in HIV and women’s health, revised and pilot
tested prior to inclusion in the survey. The revised sur-
vey with additional HIV items was translated into the
local language, Luganda, piloted in the community and
then edited and revised based on feedback for clarity.
Data was abstracted from each participant’s chart from
the HIV clinic which included clinical information such
as CD4 count, time since last appointment and blood
work, World Health Organization (WHO) HIV disease
stage [19], as well as type and duration of cART. In this
clinical setting, women do not necessarily receive clinical
blood work at each visit, but only if symptomatic or not
on cART. Data from interviews and corresponding chart
review were entered into an Access database created
from survey questions and analyzed using SPSS (v14).
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Study procedures
In November 2013, local research assistants fluent both
in English and Luganda were identified by the Ugandan
ASPIRE research coordinator and trained in collaboration
with the Canadian ASPIRE research team. In a private
location that ensured patient confidentiality and allowed
one-on-one interviews by the local research assistant, the
survey participant’s primary language was used to explain
the study, obtain informed consent, and complete the sur-
vey. After participants completed initial knowledge survey
questions, the procedure of self-collecting a sample for
HPV testing was explained by the local research assistant
using a diagram of the swab, the genital tract, and car-
toons of how to obtain self-collected sample. Surveys were
completed by consenting study participants over a three-
week period. Following completion of all survey and data
recording, a workshop tailored from survey responses was
held for study participants as an educational intervention
about HIV and cervical cancer, HPV, and cervical cancer
screening. This workshop also functioned to inform par-
ticipants of relevant findings.
In February–June 2014, all participants were contacted
by a nurse from the HIV clinic by phone and invited to
make an appointment to participate in self-collection
based HPV testing at the HIV clinic. Women who could
not be reached by phone were approached at their next
HIV follow up visit. At the time of their clinic visit,
women were instructed on how to use the self-collected
vaginal swab and asked to provide a sample in a private
room at the clinic. Specimens were tested for high risk
HPV (genotypes 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59
and 66), Neisseria gonorrhoeae and Chlamydia trachomatis
with real-time PCR. Women who tested HPV positive
were contacted by phone with results and scheduled a
colposcopy appointment for assessment at Mulago
Hospital, a tertiary care center. Women who tested
positive for N. gonorrhoeae and C. trachomatis were
offered antibiotic treatment and counseling.
Data analysis
Descriptive statistics for all survey questions, chart
review data, and screening results were generated for all
participants. Chi-square or Fisher’s exact test were used
to compare factors of interest between HPV+ and HPV-
women that participated in screening. Unadjusted odds
ratios (OR) were calculated for all variables that reached
significance of p > 0.05.
Results
Population demographics
In total 84 of 87 study participants completed the sur-
vey. Details for the demographic characteristics and
chart review data of WHIV are captured in Table 1.
WHIV in our study population were considered as
engaged with health care with over 92.9% having
attended for HIV care and monitoring in the past
6 months from chart review. Only 29.6% of women had
been living with HIV for over 5 years, and 51.9% had a
CD4 count over 350. The majority of women, 75.9%,
had HIV WHO stage I or II disease [19] at the time of
the study with 69% on an ART regimen.
Knowledge & intention to be screened
The survey responses for the knowledge, attitudes and
behaviours among WHIV in this study are captured in
Table 2. Less than 20% of WHIV reported having
received education about cervical cancer screening, and
over one third stated they never had been offered or
advised to be screened. Most women had never heard of
HPV (96.4%), while more than 60% of WHIV knew they
were at increased risk for cervical cancer due to their
HIV and were aware they needed to be screened. Of
those that were aware of HPV, WHIV often knew that
HPV risk was linked to sexual intercourse but unaware
that HPV causes cervical cancer. Only 25% of WHIV
reported condom use as their primary method of contra-
ception, and the pill was the most popular method of
contraception (27.4%), and 23.8% reported no contracep-
tion use.
Overall 98.8% of WHIV intended to provide HPV self-
collected specimens for cervical cancer screening. Only
one woman indicated that she would not be willing to
self-collect, and this was because she was pregnant at
the time of the study. Despite the high acceptability of
self-collection among WHIV, the majority of women did
not think it was necessary to be screened for cervical
cancer (98.8%). Similarly, perceived risk of HPV was low
(8.3%), while 44% of WHIV were unsure if they were at
risk. The vast majority of women (95.2%) did not see
embarrassment or concerns of how to collect the speci-
men properly as barriers to screening; nor were they
concerned others would perceive them to have cervical
cancer if they were tested for HPV (97.6%), and 69.9%
found it acceptable for an outreach worker drop off a
swab at their home.
Results from HPV testing
Of the 87 WHIV in the study, 40 (46.0%) were able to
attend the clinic to provide a self-collected sample for
high risk HPV testing. A total of 18/40 (45.0%) tested
positive for one of the 12 high risk HPV genotypes and
of those 6 (15.0%) women were positive for HPV strains
16 or 18. Among HPV positive women, 5/18 attended
follow up colposcopy assessment, one of whom was posi-
tive for HPV 16/18, and all women were negative for cer-
vical dysplasia. There were no cases of N. gonorrhoeae or
C. trachomatis in the study population. Factors associated
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with HPV positivity are included in Table 3. WHIV who
reported use of oral contraceptives were more likely to be
HPV positive (OR = 6.65, 95% CI: 1.16, 38.19; p = 0.03)
and WHIV who have had blood work within the past
6 months were more likely to be HPV positive (OR = 0.16,
95% CI: 0.03, 0.74; p = 0.02) (Table 4).
Among WHIV who participated in the study but did
not attend screening, 2 of 47 could not be reached by
phone, 5 of 47 indicated that they had screened for cer-
vical cancer elsewhere, and 40 of 47 refused to attend
the clinic. The main reasons for refusal were that dis-
tance to travel was too far, not having time to attend
screening, or did not show up for the scheduled
appointment.
Discussion
Knowledge of HPV, cervical cancer & intention to screen
Although our population in Kisenyi was highly engaged
in HIV care, less than 20% had ever received any educa-
tion around cervical cancer, 96% had never heard of
HPV, and almost 99% did not feel it was necessary to be
screened. These findings reflect a potential lack of cer-
vical cancer training among HIV care providers, and
competing health priorities in HIV positive populations.
The low percentage of women in our study who had
ever had a pelvic exam (14.5%) is further evidence of the
Table 1 Demographics and chart review characteristics of WHIV
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Mean duration of ARV
therapy in months (SD)
40.0(34.77)
On ARV Yes 58(69.0)
No 26(31.0)
Missing 3
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Table 2 Knowledge, attitudes and behaviours among WHIV
Variable Total N = 87
N(%)
Do you know someone who





What do you think causes
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potential impact that offering HPV self-collection as part
of routine HIV care could have on WHIV to enhance
the uptake of cervical cancer screening. Others have em-
phasized the need to integrate cervical cancer screening
into routine HIV care for WHIV and have documented
the impact of missed opportunities for education about
cervical cancer by HIV care providers [20]. Despite this,
data from South Africa, a country with significantly
more health resources than Uganda, illustrates the posi-
tive impact of increased infrastructure on health educa-
tion with over 85% of WHIV aware of cervical cancer
screening [21].
Self-collection based HPV testing for cervical cancer
screening
In this group of WHIV engaged in care, there was a high
prevalence of oncogenic HPV types (45.0%), a large pro-
portion of which were HPV 16 or 18 (15%). This is
much higher than other studies that ASPIRE has con-
ducted in Kisenyi where HPV positivity rates among
HIV negative women was only 28.9%, of which 5.3%
were HPV 16 or 18 [22]. Our HIV positive population
was more likely to live or work outside of Kisenyi, com-
pared to past studies where self-collection was offered
by community outreach workers at their homes [23, 24].
This suggests that a model for screening with self-
collection for WHIV may be more appropriately based
out of a health center, as these women are already
engaged in care, thereby avoiding unnecessary travel.
Unlike the present study where many women were asked
to attend self-collection outside of their normal HIV
appointment schedule; had screening been integrated
with routine HIV care, uptake and follow-up would have
undoubtedly been higher. Uptake of self-collection based
screening in Kisenyi was 99% in a recent study [24], and
a subgroup analysis demonstrated 95% uptake among
WHIV [22]. Similarly, we believe that the distance to the
tertiary care hospital where colposcopy is conducted, as
well as the time required for the additional visit were
barriers to follow up assessment. Competing priorities,
lack of perceived risk, and cost are likely important fac-
tors that have made colposcopy follow up adherence a
challenge in this, and other studies our team has con-
ducted in this community [24].
In our population, women who were taking oral con-
traceptives were more likely to be HPV positive. This is
consistent with other studies, although the literature
around the role of oral contraceptive on HPV positivity
is unclear and in need of further study [25, 26]. Women
who had taken blood work within the last 6 months
were also more likely to be HPV positive. Since blood
work is usually only performed on women who are
symptomatic, it is possible that HPV is more persistent
in these women.
Limitations and policy implications
This study was limited by its small sample size, which
prevented us from conducting further statistical testing
such as logistic regression. Another limitation was that a
large proportion of our original survey population was
unavailable to attend screening. Due to limitations on
the study timeline, we were unable to offer screening
during a routine HIV clinical visit to demonstrate an
integrated approach. Despite this, we feel our results
demonstrate the feasibility of a self-collection based
approach to screening, while underscoring the chal-
lenges of offering interventions in a siloed manner.
Despite alarmingly low levels of knowledge of HPV,
global expansion of the HPV vaccine in countries including
Uganda offers the opportunity for community health
workers to engage and educate girls, women and their
families on cervical cancer prevention. Self-collection
for HPV screening has been demonstrated as a highly
acceptable and effective method of cervical cancer
screening, particularly in susceptible populations such
as WHIV [14, 15]. This highly scalable model can be
adapted and implemented in various ways to improve
access using minimal infrastructure. In community-
based models for HPV self-collection, community out-
reach workers can be used to offer women screening at
their homes or places of work. There is also huge potential
for this type of screening to be offered in an integrated
manner, where screening can be combined with other
Table 2 Knowledge, attitudes and behaviours among WHIV
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health services such as maternal/child or reproductive
health services. Given the higher rates of cervical cancer
among WHIV, screening should without question be inte-
grated with routine HIV appointments. HIV clinics are
often already equipped with the necessary human
resources and infrastructure needed to implement self-
collection based screening and follow up, including a
laboratory where HPV testing can be performed. Of note,
colposcopy and early curative treatment would need to be
more readily accessible for effective scale up of a compre-
hensive cervical cancer screening program.
Conclusions
To not integrate prevention of cervical cancer in HIV
care would do a great disservice to the accomplishments
that have been made in the management of HIV. The
overwhelming and growing need for accessible and
effective screening in WHIV at risk for cervical cancer
should compel us to look at feasible methods on a large
scale. Our study of WHIV in this LMIC setting demon-
strates the potential for HPV self-collection to be inte-
grated into routine HIV care at a community level.
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